News from sierra oncology A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 12, 2021, 07:00 ET Sierra Oncology Announces Presentation at LifeSci Partners Precision Oncology Day

SAN MATEO, Calif., Feb. 12, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted...

Feb 09, 2021, 07:00 ET Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN MATEO, Calif., Feb. 9, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted...

Jan 05, 2021, 07:00 ET Sierra Oncology to Present at H.C. Wainwright 2021 BioConnect Virtual Conference

VANCOUVER, BC, Jan. 5, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted...

Dec 07, 2020, 10:00 ET Sierra Oncology Announces Momelotinib Data for Intermediate / High-risk Myelofibrosis Patients with Lower Baseline Platelet Counts

--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count--...

Dec 05, 2020, 10:30 ET Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting

--Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020...

Dec 01, 2020, 07:00 ET Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH

--Sierra Chief Development Officer Barbara Klencke to be joined by renowned myelofibrosis experts Jean-Jacques Kiladjian, Ruben Mesa and Srdan...

Nov 25, 2020, 07:00 ET Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

VANCOUVER, BC, Nov. 25, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution,...

Nov 12, 2020, 07:00 ET Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference

VANCOUVER, BC, Nov. 12, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution,...

Nov 05, 2020, 08:00 ET Sierra Oncology to Report Momelotinib Long-term Overall Survival Data in Oral Presentation at ASH 2020

- Efficacy data for momelotinib in myelofibrosis patients by baseline platelet levels also to be presented - VANCOUVER, BC, Nov. 5, 2020 /PRNewswire/ ...

Nov 05, 2020, 07:00 ET Sierra Oncology Reports Third Quarter 2020 Results

- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - VANCOUVER, BC, Nov. 5, 2020 /PRNewswire/ - Sierra...

Oct 02, 2020, 07:00 ET Sierra Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC, Oct. 2, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and...

Sep 14, 2020, 07:00 ET Sierra to Present at September Investor Conferences

VANCOUVER, BC, Sept. 14, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and...

Aug 06, 2020, 07:05 ET Sierra Oncology Strengthens Management Team to Implement North American Pre-Commercialization Strategy for Momelotinib

- Kevin Norrett appointed Chief Business Officer – - William D. Turner appointed Chief Regulatory and Technical Operations Officer – VANCOUVER, BC,...

Aug 06, 2020, 07:00 ET Sierra Oncology Reports Second Quarter 2020 Results

- MOMENTUM Phase 3 clinical trial enrollment on track; top-line data anticipated in H1 2022 - - Updated analyses comparing symptomatic benefits of...

Jun 12, 2020, 02:30 ET Sierra Oncology Reports Favorable Long-Term Safety and Dose Intensity Data for Momelotinib

- Data presented at the 25th European Hematology Association (EHA) Virtual Congress further demonstrate the potential anemia benefits and favorable...

May 27, 2020, 07:00 ET Sierra Oncology Announces Presentations at Upcoming Investor Conferences

- Oppenheimer Biotech by the Lake 2020 Investor Summit at 11:25 a.m. ET on May 28th – - Jefferies Global Virtual Healthcare Conference at 4:30 p.m....

May 26, 2020, 07:00 ET Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer

- Mr. Craig Collard appointed to the Board of Directors - VANCOUVER, May 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug...

May 14, 2020, 09:00 ET Sierra Oncology to Report Favorable Dose Intensity Data and Long-Term Safety Data for Momelotinib at the 25th European Hematology Association (EHA) Congress

- Momelotinib's demonstrable anemia benefit and low myelosuppressive potential facilitate sustained dose intensity and prolonged clinical activity -...

May 07, 2020, 08:00 ET Sierra Oncology to Hold KOL Call to Discuss Anemia & Transfusion Dependency as Critical Unmet Needs in Myelofibrosis

- Event featuring renowned myelofibrosis expert Dr. Ruben Mesa scheduled for 10:00 am ET on Wednesday, May 13th - VANCOUVER, May 7, 2020 /PRNewswire/ ...

May 07, 2020, 07:00 ET Sierra Oncology Reports First Quarter 2020 Results

- Company continues to operationalize the MOMENTUM Phase 3 clinical trial in myelofibrosis - - Impact of COVID-19 uncertain but may potentially...

Mar 03, 2020, 07:00 ET Sierra Oncology Reports 2019 Year End Results

- MOMENTUM Phase 3 clinical trial for momelotinib underway, targeting enrolment of 180 patients with myelofibrosis who are symptomatic and anemic - - ...

Feb 26, 2020, 07:00 ET Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call

VANCOUVER, Feb. 26, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and...

Feb 25, 2020, 07:00 ET Sierra Oncology to Present at the Cowen 40th Annual Health Care Conference

-"Building MOMENTUM for Patients with Myelofibrosis" scheduled for 10:00 a.m. ET on March 4, 2020 - VANCOUVER, Feb. 25, 2020 /PRNewswire/ - Sierra...

Feb 06, 2020, 07:00 ET Sierra Oncology Completes Conversion of Preferred to Common Stock and Issues Stock to Gilead

VANCOUVER, Feb. 6, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the development and...

Jan 22, 2020, 07:00 ET Sierra Oncology Announces Reverse Stock Split

- Preferred shares issued in recently completed $103M financing to convert to common shares - - Gilead to become shareholder in Sierra in accordance...